ADI 100
Alternative Names: ADI™-100Latest Information Update: 22 Apr 2025
At a glance
- Originator ADiTxT Therapeutics
- Developer Adimune; ADiTxT Therapeutics
- Class Antihyperglycaemics; Antipsoriatics; Antispastics; DNA; Gene therapies
- Mechanism of Action Apoptosis stimulants; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Psoriasis; Stiff-person syndrome; Type 1 diabetes mellitus
Most Recent Events
- 15 Apr 2025 Preclinical trials in Stiff-person syndrome in USA (unspecified route), prior to April 2025
- 15 Apr 2025 Pharmacodynamics data from a preclinical trial in Autoimmune disorders released by Adimune
- 14 Apr 2025 Aditxt plans for filling of clinical trial applications for psoriasis, Type 1 diabetes mellitus and Stiff-person syndrome with the German Health Authority and US FDA in the second half of 2025